BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | 0.01 | -122.20 | -0.16 |
| FCF Yield | -0.84% | 2.19% | -1.77% | -0.38% |
| EV / EBITDA | 0.00 | 88.91 | 91.79 | -1,835.79 |
| Quality | ||||
| ROIC | 0.00% | 7.30% | 0.26% | -1.40% |
| Gross Margin | 98.63% | 98.29% | 96.86% | 95.34% |
| Cash Conversion Ratio | 3.19 | 8.12 | -859.91 | 0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.61% | 22.05% | 20.23% | 18.50% |
| Free Cash Flow Growth | -132.74% | 248.67% | -369.77% | -171.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 22.90 | 28.06 | -570.99 |
| Interest Coverage | -1.51 | 1.38 | 0.90 | -0.18 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.55 | 0.66 | 0.76 |
| Cash Conversion Cycle | 0.00 | -63.79 | -4.82 | 1.89 |